Andrea Mignatti

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/12d96620-5dc2-11ee-bca8-e9237785e4a3.jpg

First Name

Andrea

Last Name

Mignatti

NPI

1245464577

Faculty ID

17584

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

57045

Is Open Scheduling

Off

Michael L. Lipton

https://assets.montefioreeinstein.org/profiles/images/Lipton_Michael_MD_420x504.jpg

First Name

Michael

Last Name

Lipton

NPI

1366535502

Faculty ID

148

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>Michael L. Lipton, M.D., Ph.D., F.A.C.R.</strong><br />Dr. Lipton, a neuroradiologist and neuroscientist, is Associate Director of the Gruss Magnetic Resonance Research Center at Einstein and &nbsp;Medical Director of MRI Services for Montefiore Health, both in New York. He divides his professional time between the clinical practice of neuroradiology, teaching and research. Dr. Lipton&rsquo;s research broadly addresses the use of advanced noninvasive imaging technology to reveal heretofore-inaccessible substrates of brain dysfunction, particularly in the realms of behavior and cognition. More specifically, his research program has focused for nearly a decade on detecting and characterizing the effects of mild brain injury (AKA concussion). Specific areas of emphasis at present include the understanding of inter-individual differences in the manifestations of brain injury and the cumulative effects of repetitive subconcussive injury in sports. Dr. Lipton&rsquo;s work on the impact of subconcussive &ldquo;heading&rdquo; on brain structure and function in amateur soccer players, funded by the Dana Foundation and the National Institutes of Health, has been reported extensively in the press worldwide.</p>

Research Areas

Research Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<p>Dr. Lipton develops and applies advanced quantitative MRI to enhance characterization of brain disease in patients with persistent symptoms related to traumatic brain injury and other disorders that are not adequately visualized using conventional imaging approaches</p>

Research Focus

<p>Dr. Lipton applies advanced imaging technology to characterize the effects of trauma on behavior and cognition. His work on repeated subconcussive head impacts in soccer players has been reported extensively in the press worldwide.</p>

Elsevier Profile

Biography

<p>Michael L. Lipton, MD, PhD, FACR, is the Medical Director of MRI Services and an Attending Radiologist at Montefiore. He is also a Professor of Radiology, Psychiatry and Behavioral Sciences at our Albert Einstein College of Medicine. Dr. Lipton has been a member of the Montefiore team since 1997, with a clinical focus on developing advanced quantitative MRI to enhance characterization of brain diseases. He works primarily with patients who suffer persistent symptoms related to traumatic brain injury and other disorders that are not easily identified with conventional imaging approaches. </p><p>Dr. Lipton received his Doctor of Medicine from Boston University in 1990. He continued his studies by attending our Albert Einstein College of Medicine, where he received his Master of Science with Distinction and his Doctor of Philosophy in Neuroscience. His postgraduate training began with an internship in internal medicine at Brookdale Hospital Medical Center completed in 1991. Over 5 years, Dr. Lipton completed a residency and chief residency in diagnostic radiology, followed by a 2-year fellowship in neuroradiology at Montefiore, completing his postgraduate training in 1997. </p><p>Dr. Lipton has completed substantial research on repeated subconcussive head impacts in sports, particularly in soccer players. His work on this topic has been reported on extensively in the press worldwide. Dr. Lipton?s other research focuses mainly on the brain and has been shared in a number of presentations internationally, as well as published in numerous books and papers. </p><p>In 2017, Dr. Lipton received the Distinguished Investigator Award from the Academy of Radiology and Biomedical Imaging Research. Dr. Lipton is board certified by the American Board of Radiology, is a Fellow of the American College of Radiology and is a member of numerous professional societies, including the the American Medical Association, and the American Society of Neuroradiology. </p>

Is Open Scheduling

Off

Asma Khaliq

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Asma

Last Name

Khaliq

NPI

1992937437

Faculty ID

17481

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

131628

Is Open Scheduling

Off

Shiu M. Young

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Shiu

Last Name

Young

NPI

1467742726

Faculty ID

14110

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5826

Is Open Scheduling

Off

Danny Woo

https://assets.montefioreeinstein.org/profiles/images/physphoto/Woo_Danny_MD_420x504.jpg

First Name

Danny

Last Name

Woo

NPI

1639272057

Faculty ID

3618

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3880

Is Open Scheduling

Off

Samson Wiseman

https://assets.montefioreeinstein.org/profiles/images/physphoto/Wiseman_Samson_MD_420x504.jpg

First Name

Samson

Last Name

Wiseman

NPI

1588761316

Faculty ID

10181

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4748

Is Open Scheduling

Off

Daniel A. Weiser

https://assets.montefioreeinstein.org/profiles/images/Weiser_Daniel_MD_2x.jpg

First Name

Daniel

Last Name

Weiser

NPI

1225239700

Faculty ID

13846

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><span style="text-decoration: underline;"><strong>Childhood cancer research laboratory</strong></span></p>
<p>Our laboratory is focused on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. In such patients with typically incurable cancer, we are striving to identify new approaches to and types of treatment. We have multiple ongoing projects:</p>
<p><strong>+ Identification of biologic drivers of ultra-high-risk neuroblastoma</strong>. Neuroblastoma is one of the most common and deadly childhood cancers. Despite intensive research, there are limited therapeutic strategies for patients with <em>de novo </em>chemotherapy resistance that leads to particularly poor outcomes. We have been studying neuroblastoma since 2009 and are identifying additional biologic drivers of highly lethal tumors.</p>
<p>We compare tumor features from patients with early death from tumor progression compared to those with a maintained complete response. We assess unique histo-morphologic and proteomic features and computationally integrate these data with genomic and transcriptomic datasets to develop a combined predictor of primary refractory disease. Patients with this entity require non-standard and/or intensified treatment. Oncogenic drivers are being characterized in the lab which will facilitate strategies for novel pharmacologic intervention.</p>
<p><strong>+ Characterization of neuroblastoma development from neural crest cells</strong>.&nbsp; We are studying pathways and interactions that results in uncontrolled cell proliferation early in neuroblastoma development with an ultimate goal of identifying new targets and approaches for pharmacologic intervention.</p>
<p><strong>+ Evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma</strong>.&nbsp; With expected outcomes lagging behind those of more common childhood cancers, children with neuroblastoma require new approaches to treatment. Our lab works with multiple international clinical and research consortium groups to perform preclinical studies that substantiate human clinical trials.&nbsp;</p>
<p><strong>+ Detection of circulating tumor DNA in osteosarcoma</strong>. With no reliable non-invasive approach for disease monitoring during and after treatment, we are applying cutting edge next-generation sequencing approaches to identify solid tumors with a blood-based &ldquo;liquid&rdquo; biopsies. This will allow clinicians to assess tumor responsiveness to chemotherapy and predict likelihood of recurrence.</p>
<p><strong>+ Assessment of accelerated aging using miRNA-seq in survivors of childhood cancer</strong>. Chemotherapy has many untoward effects on healthy cells and leads to many signs of accelerated aging in children treated for cancer. Using a known microRNA &ldquo;aging&rdquo; signature discovered at Albert Einstein College of Medicine, we are studying what causes this phenotype in childhood cancer, with a goal of offering improved intervention to minimize long-term toxicity of treatment.</p>
<p><strong><span style="text-decoration: underline;">Physician Summary</span></strong></p>
<p>Daniel A. Weiser, MD, is board-certified in pediatric hematology/oncology with clinical expertise in neuroblastoma and other tumors of the adrenal glands, kidneys, liver, and gonads. He is the medical director of the intra-abdominal solid tumor program at the Children&rsquo;s Hospital at Montefiore and brings together a highly specialized multi-disciplinary care team to provide comprehensive treatment for diverse pediatric malignancies. In addition, Dr. Weiser directs a childhood cancer research laboratory that focuses on the identification of new targeted agents for cancer therapy, especially in the treatment of rare and aggressive malignancies such as neuroblastoma. His research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise for improving management of all patients with solid tumors.</p>
<p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Advances in Neuroblastoma Research Association (ANRA), National Pediatric Cancer Foundation (NPCF), and the American Academy of Pediatrics (AAP). He has received numerous awards including the Brigid Leventhal Special Merit Award from ASCO and the Conquer Cancer Foundation, and a prestigious K12 from the National Cancer Institute for the training of the next generation of physician-scientists in pediatric cancer. Dr. Weiser is actively involved in teaching and mentorship of trainees, and takes great pride in providing advanced and compassionate care to his patients and their families.</p>
<p><strong>Clinical Expertise</strong></p>
<ul>
<li>Neuroblastoma (adrenal tumors)</li>
<li>Wilms tumor (renal tumors)</li>
<li>Hepatoblastoma (liver tumors)</li>
<li>Germ cell tumors (including testicular and ovarian tumors)</li>
<li>Thyroid and other rare tumors</li>
<li>Experimental therapeutics</li>
<li>Cancer genetics and biomarkers</li>
</ul>
<p><strong>Board Certifications</strong></p>
<ul>
<li>Pediatrics</li>
<li>Pediatric Hematology/Oncology</li>
</ul>
<p><strong>Professional Education</strong></p>
<ul>
<li>M.D. &ndash; Stony Brook University, NY</li>
<li>Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Chief Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Fellowship &ndash; The Children&rsquo;s Hospital of Philadelphia, PA</li>
</ul>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

DR. Weiser's clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma, and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers.&nbsp;

Research Focus

Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others.

Elsevier Profile

EMR ID

5755

Biography

<p>Daniel A. Weiser, MD, is a Medical Director of the Intra-abdominal Solid Tumor Program in the Pediatrics Hematology/Oncology department at Children&rsquo;s Hospital at Montefiore. He is also Associate Professor in the Pediatrics and Genetics departments at the Albert Einstein College of Medicine. His clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers. Dr. Weiser is actively involved in teaching and mentorship of trainees and takes great pride in his active participation in patient care.</p><p>Dr. Weiser received his Bachelor of Science in Neurobiology in 1995 at Haverford College, PA. In 2004, he received his Doctor of Medicine at Stony Brook University School of Medicine, NY. He is currently earning his Master of Science in Translational Research at the University of Pennsylvania. He began a residency in Pediatrics at the New York-Presbyterian, Columbia University in 2007. Dr. Weiser then completed a three-year fellowship in Pediatric Hematology/Oncology at The Children&rsquo;s Hospital of Philadelphia. </p><p>Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others. His research has been published in many reviewed journals. </p><p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and the American Academy of Pediatrics (AAP). He has received many awards including the Brigid Leventhal Special Merit Award through ASCO, and he has been awarded a prestigious K12 from the NCI for the training of the next generation of physician-scientists in pediatric cancer.</p><p>He is board certified in Pediatric Hematology/Oncology and General Pediatrics.</p>

Is Open Scheduling

Off

Peter L. Tenore

https://assets.montefioreeinstein.org/profiles/images/9816-tenore.jpg

First Name

Peter

Last Name

Tenore

NPI

1316063027

Faculty ID

9816

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

Dr. Tenore is a Medical Director in the Division of Substance Abuse and is a wekk known figure in this field, having published in several journals and providing education in substance abuse to local and state agencies. He is an advisor to the New York State Ofice of Alcoholism and Substance Abuse Services and the federal Center for Substance Abuse Treatment. He is certified in Internal Medicine and by examination in Addiction Medicine and a New York State HIV Provider. His particular interests are management of cocaine and other addictions as well as providing hepatitis C and HIV treatment in the methadone clinic setting.

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

DINO-VAMP: A Helpful Acronym in Determining Optimal Methadone Dosing and Brief review of Dosing Literature, Journal of Maintenance in the Addictions, Vol.2(4).

Guidance On Optimal Methadone Dosing, Addiction Treatment Forum, Vol.12 (2).

Methadone:A Medical Model in "Innovations in Substance Abuse Treatment and Policy," Yale University Center for Interdisciplinary Research, Yale Publicatinos, New Haven, CT.

Three Oral Formulations of Methadone: A Clinical and Pharmacodynamic Comparison, Journal of Substance Abuse Treatment, Vol. 17(3), Gourevitch, Hartell, Tenore, et al.

EMR ID

3901

Is Open Scheduling

Off

Nicola Tarantino

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/870a5060-5fa7-11ec-9773-d197dc92a0d8.jpg

First Name

Nicola

Last Name

Tarantino

NPI

1669954558

Faculty ID

17681

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

13854

Visit Type ID

2497

Is Open Scheduling

Off

Zocdoc Link

Melissa R. Stein

https://assets.montefioreeinstein.org/profiles/images/physphoto/Stein_Melissa_MD_LC_2013_06-18.jpg

First Name

Melissa

Last Name

Stein

NPI

1699865592

Faculty ID

9444

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>Current Investigations</strong></p>

<ol start="1" style=" margin-bottom: 0in;" type="1">
<li>Development of an Objective Structured Clinical Examination (OSCE) in Substance Abuse</li>
</ol>

<p>&#160;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4263

Is Open Scheduling

Off